[Skip to Content]

Upstate Active Clinical Trials

Study Title:

RU051417I - Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-
Etoposide) and Lenalidomide-R-ICE (R2-ICE) in Patients with First-Relapse/Primary Refractory Diffuse
Large B-Cell Lymphoma (DLBCL)

What is the purpose of the study?

The purpose of this study is to find out what effects, good and/or bad, the addition of lenalidomide to standard chemotherapy (R-ICE) has on you and your cancer. The combination of Lenalidomide with standard chemotherapy is also referred to as R2-ICE.

Upstate Institutional Review Board (IRB) Number:

840308

Study/Protocol ID:

RU051417I

Study Phase:

Phase II

Patient Age Group:

Adults

Principal Investigator:

Teresa C Gentile, MD, PhD

What is involved if I participate?

  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    No

Where will the study take place?

Upstate Hospital

ClinicalTrials.Gov ID:

NCT02628405

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Corey Chase
Phone: 315-464-4187
Email: chasec@upstate.edu

Return to Previous Page || Search Again

Top